Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2Withdrawn 1Completed 1Available 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Dermatologic 1

Conditions

Nevus, Blue 1Melanoma 1Advanced or Metastatic Solid Tumors 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × tebentafusp × Clear all
NCT05549297 2026-02-25

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Immunocore Ltd

Phase 3 Recruiting
540 enrolled
Dermatologic

Melanoma, Nevus, Blue

NCT05785754 2025-06-26

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

DynamiCure Biotechnology

Phase 1 Recruiting
320 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡